A Phase 1a/b Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19
Latest Information Update: 11 May 2026
At a glance
Most Recent Events
- 28 Apr 2026 According to an OPKO Health media release, trial initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19.
- 06 Mar 2026 New trial record
- 26 Feb 2026 According to Opko Health media release, the trial is scheduled to begin in the second quarter of 2026, with pharmacokinetic and immunogenicity data expected later this year.